GO:0035774 positive regulation of insulin secretion involved in cellular response to glucose stimulus: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035774 describes any process that increases the frequency, rate or extent of regulated insulin release in response to glucose, a core function of pancreatic beta cells.
• Biphasic insulin secretion depends on distinct granule pools, cytoskeletal remodeling, small GTPases and SNARE-mediated membrane fusion.
• Glucose metabolism raises ATP/ADP, closes KATP channels, depolarizes the beta cell and triggers Ca2+-dependent exocytosis.
• Human beta cell lines such as 1.1B4 and 1.1E7 provide tractable models for studying positive regulation of insulin secretion.
• Sympathetic innervation and alpha-adrenergic signaling can desensitize insulin secretion, showing that this process is subject to neural modulation.
• CRISPR knockout, knock-in and overexpression models enable causal testing of candidate genes in this pathway.
Description
GO:0035774, positive regulation of insulin secretion involved in cellular response to glucose stimulus, is a biological process term that captures the mechanisms by which glucose increases the regulated release of insulin from cells. It is a child of the broader regulation of insulin secretion and is central to understanding how pancreatic beta cells match insulin output to blood glucose. The term is used in functional enrichment and pathway annotation to describe gene products that enhance, rather than merely permit, glucose-stimulated insulin secretion. Because insulin secretion is biphasic, with a rapid first phase and a sustained second phase, positive regulation involves distinct molecular events including granule trafficking, docking and fusion. Researchers study this process to dissect beta cell physiology, to model diabetes-related defects and to identify targets that can restore or amplify insulin release. Experimental systems range from primary islets to engineered human beta cell lines that retain glucose responsiveness. Neural inputs, such as sympathetic innervation, can also modulate the set point of insulin secretion, adding another layer of regulation.
positive regulation of insulin secretion involved in cellular response to glucose stimulus At A Glance
| GO ID | GO:0035774 |
|---|---|
| GO term | positive regulation of insulin secretion involved in cellular response to glucose stimulus |
| Ontology | biological_process |
| Synonym | positive regulation of insulin secretion in response to glucose |
| Definition | Any process that increases the frequency, rate or extent of the regulated release of insulin that contributes to the response of a cell to glucose. |
| Major function | Enhancement of glucose-stimulated insulin exocytosis in pancreatic beta cells |
| Related processes | Insulin secretion, glucose sensing, granule exocytosis, biphasic secretion |
| Cellular context | Pancreatic beta cells and insulin-secreting cell lines |
| Disease relevance | Type 2 diabetes, beta cell dysfunction, insulin secretion disorders |
What Is GO:0035774?
In our own words, GO:0035774 refers to any biological process that increases the frequency, rate or extent of regulated insulin release specifically as part of a cellular response to glucose. It is not the mere presence of insulin or the capacity to secrete it, but an active positive modulation of the secretion machinery when glucose is elevated. The term is a biological process annotation and is synonymous with positive regulation of insulin secretion in response to glucose.
Why Is positive regulation of insulin secretion involved in cellular response to glucose stimulus Important in Cell Biology?
GO:0035774 matters because insulin secretion is the principal mechanism by which the body lowers blood glucose, and its positive regulation determines the magnitude and timing of that response. Defects in this process contribute to hyperglycemia and diabetes, while enhancing it is a therapeutic goal. The term also provides a precise annotation for interpreting transcriptomic and proteomic data from beta cells, helping researchers distinguish genes that actively amplify secretion from those that are merely housekeeping.
• Defines the molecular logic of glucose-stimulated insulin secretion, a hallmark of beta cell function.
• Provides a framework for understanding biphasic insulin release and granule pool dynamics.
• Helps interpret gene expression changes in diabetes models and human islet studies.
• Supports target discovery for therapies that aim to boost endogenous insulin secretion.
• Enables functional annotation of GWAS loci associated with insulin secretion traits.
• Guides the use of human beta cell lines for reproducible secretion assays.
• Explains how neural and adrenergic inputs can shift the set point of insulin release.
• Underpins CRISPR-based causal testing of candidate regulators in beta cells.
What Happens During positive regulation of insulin secretion involved in cellular response to glucose stimulus?
Glucose sensing and metabolic triggering
In simple terms: The beta cell tastes glucose and converts it into a signal to release insulin.
Glucose enters the beta cell and is metabolized, raising the ATP/ADP ratio. This closes ATP-sensitive potassium channels, depolarizes the plasma membrane and opens voltage-gated calcium channels. The resulting calcium influx is the trigger for insulin granule exocytosis. Positive regulation of this step increases the efficiency or sensitivity of glucose sensing, thereby amplifying the secretory response.
Granule trafficking and cytoskeletal remodeling
In simple terms: Insulin granules must be moved to the cell membrane before they can be released.
Insulin granules are transported along microtubules and actin filaments. Small GTPases and their effectors regulate cytoskeletal rearrangements that bring granules into proximity with the plasma membrane. Positive regulation of insulin secretion often involves enhancing granule mobilization from reserve pools, which is critical for the sustained second phase of release.
Docking and priming of granules
In simple terms: Granules are parked and made ready at the membrane.
Docking and priming involve interactions between granule proteins and plasma membrane t-SNAREs, preparing granules for rapid fusion. SNARE proteins and accessory factors such as Munc18 and synaptotagmins are essential for this step. Positive regulation can act by increasing the number of primed granules or by lowering the calcium threshold for fusion.
Calcium-triggered membrane fusion and first-phase release
In simple terms: Calcium acts like a key that unlocks granule fusion.
A rise in cytosolic calcium triggers synaptotagmin-dependent fusion of primed granules with the plasma membrane, releasing insulin. This corresponds to the rapid first phase of secretion. Positive regulation of this step enhances the probability or speed of fusion, contributing to the sharp initial insulin spike after glucose stimulation.
Second-phase secretion and granule replenishment
In simple terms: The cell keeps releasing insulin as long as glucose stays high.
Sustained secretion requires continuous recruitment of granules from reserve pools and their priming. This second phase depends on metabolic signaling, cytoskeletal dynamics and SNARE-mediated fusion. Positive regulation of insulin secretion can increase the rate of granule replenishment or prolong the secretory burst, thereby shaping the overall insulin profile.
Key Genes Involved in GO:0035774 positive regulation of insulin secretion involved in cellular response to glucose stimulus
The following genes and proteins are established players in glucose-stimulated insulin secretion and its positive regulation, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| INS | Encodes insulin, the cargo of secretory granules | Core readout of beta cell function |
| GCK | Glucokinase, rate-limiting glucose sensor | Determines glucose threshold for secretion |
| SLC2A2 | GLUT2 glucose transporter | Facilitates glucose uptake in rodent beta cells |
| KCNJ11 | Kir6.2 subunit of KATP channel | Controls membrane depolarization |
| ABCC8 | SUR1 subunit of KATP channel | Regulates KATP channel activity |
| CACNA1A | Voltage-gated calcium channel subunit | Mediates calcium influx for exocytosis |
| STX1A | Syntaxin-1A, t-SNARE | Essential for granule docking and fusion |
| SNAP25 | t-SNARE component | Forms SNARE complex with syntaxin and VAMP |
| VAMP2 | v-SNARE on insulin granules | Mediates granule-plasma membrane fusion |
| RAB3A | Small GTPase on granules | Regulates granule trafficking and priming |
| RAB27A | Small GTPase on granules | Controls granule docking and exocytosis |
| SYT7 | Synaptotagmin-7 | Calcium sensor for second-phase secretion |
| MUNC18-1 | STXBP1, SNARE regulator | Chaperones syntaxin and regulates fusion |
| PCLO | Piccolo, presynaptic cytomatrix protein | Modulates granule pool dynamics |
| ADCYAP1 | PACAP, neuropeptide | Potentiates glucose-stimulated insulin secretion |
| GCG | Glucagon | Paracrine regulator of insulin secretion |
| SSTR2 | Somatostatin receptor | Inhibitory modulation of secretion |
How Is positive regulation of insulin secretion involved in cellular response to glucose stimulus Regulated?
Positive regulation of insulin secretion is itself regulated by multiple inputs. Glucose metabolism provides the primary trigger, but neural and hormonal signals can modulate the response. For example, chronic sympathetic innervation of islets in transgenic mice leads to differential desensitization of alpha-adrenergic inhibition of insulin secretion, indicating that adrenergic tone can reset the sensitivity of the secretory machinery. This shows that the process is not a fixed reflex but is subject to adaptive regulation by the autonomic nervous system.
positive regulation of insulin secretion involved in cellular response to glucose stimulus and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KCNJ11 | Neonatal diabetes, hyperinsulinism | Point-mutation knock-in in beta cell line |
| ABCC8 | Neonatal diabetes, hyperinsulinism | Knockout and rescue in human beta cells |
| GCK | MODY2, hyperglycemia | Knock-in of patient variants |
| INS | Neonatal diabetes, insulinopathy | Tagged knock-in for granule tracking |
| SLC2A2 | Fanconi-Bickel syndrome | Knockout in rodent beta cells |
Type 2 diabetes and beta cell dysfunction
Impaired positive regulation of insulin secretion is a hallmark of type 2 diabetes. Defects in glucose sensing, granule trafficking or exocytosis can reduce insulin output and contribute to hyperglycemia. Studying this GO term helps identify which steps are compromised in patient islets and which can be targeted therapeutically.
Monogenic diabetes and channelopathies
Mutations in genes such as KCNJ11 and ABCC8, which encode KATP channel subunits, alter the triggering pathway for insulin secretion and cause neonatal diabetes or hyperinsulinism. These conditions illustrate how disruption of positive regulation can lead to either too little or too much insulin release.
Neuroendocrine and autonomic modulation
Altered sympathetic innervation can desensitize alpha-adrenergic inhibition of insulin secretion, as shown in transgenic mouse models. This suggests that neural inputs can contribute to dysregulated insulin release in metabolic disease.
From positive regulation of insulin secretion involved in cellular response to glucose stimulus-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X enhance glucose-stimulated insulin secretion? | CRISPR knockout in human beta cell line |
| Does a patient variant alter secretion? | Point-mutation knock-in |
| Where is the protein localized during secretion? | Tagged knock-in with fluorescent tag |
| Can overexpression rescue a secretion defect? | Overexpression in beta cell line |
| Which genes are essential for biphasic secretion? | CRISPR library screening |
| How does neural input modulate secretion? | Transgenic mouse with altered innervation |
How to Study the positive regulation of insulin secretion involved in cellular response to glucose stimulus Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Insulin concentration | Static secretion assays |
| Perifusion | Dynamic insulin release | Biphasic secretion profiling |
| Live-cell imaging | Granule movement and fusion | Mechanistic studies |
| Patch-clamp | Ion channel activity | Glucose sensing and depolarization |
| Calcium imaging | Intracellular calcium | Triggering pathway analysis |
| RNA-seq | Gene expression | Candidate discovery |
| Proteomics | Protein abundance and modifications | Pathway annotation |
Static and dynamic insulin secretion assays
Insulin release can be measured by ELISA or radioimmunoassay under static incubation or perifusion conditions. These assays quantify both first and second phase secretion and are the primary readout for GO:0035774.
Live-cell imaging of granule dynamics
Fluorescently tagged insulin or granule markers allow tracking of granule trafficking, docking and fusion in real time. This reveals how positive regulators alter granule behavior.
Electrophysiology and calcium imaging
Patch-clamp and calcium indicators measure the electrical and calcium signals that trigger secretion. They help pinpoint whether a gene acts on glucose sensing, depolarization or calcium influx.
Transcriptomic and proteomic profiling
RNA-seq and proteomics of beta cells under glucose stimulation can identify genes and proteins whose expression or modification correlates with enhanced secretion. These datasets can be annotated with GO:0035774 to prioritize candidates.
How CRISPR Can Be Used to Study GO:0035774 positive regulation of insulin secretion involved in cellular response to glucose stimulus
Knockout
CRISPR knockout of candidate genes in beta cell lines or primary islets can test whether they are required for positive regulation of insulin secretion. Loss of function followed by secretion assays reveals essential players.
Point Mutation
Introducing patient-specific point mutations into genes such as KCNJ11 or GCK allows precise modeling of secretion defects. These models can show how single amino acid changes alter glucose responsiveness.
Knock-in
Knock-in of fluorescent or affinity tags enables visualization and purification of granule proteins. Tagged insulin or SNARE proteins help track granule dynamics and interactions.
Overexpression
Overexpression of candidate positive regulators can test sufficiency: does increased dosage enhance glucose-stimulated insulin secretion? This complements knockout studies and can identify rate-limiting factors.
How EDITGENE Supports positive regulation of insulin secretion involved in cellular response to glucose stimulus Research
Researchers studying positive regulation of insulin secretion involved in cellular response to glucose stimulus-related genes often need to determine whether a candidate gene is causally involved, which variant matters, and how the protein behaves in live beta cells. EDITGENE provides the CRISPR tools and cell models to answer these questions with rigor.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of insulin secretion involved in cellular response to glucose stimulus research.
Frequently Asked Questions About positive regulation of insulin secretion involved in cellular response to glucose stimulus
What is GO:0035774?
GO:0035774 is the Gene Ontology term for positive regulation of insulin secretion involved in cellular response to glucose stimulus, describing processes that increase regulated insulin release in response to glucose.
What genes are involved in positive regulation of insulin secretion?
Key genes include INS, GCK, KCNJ11, ABCC8, STX1A, SNAP25, VAMP2, RAB3A and RAB27A, among others.
How is glucose-stimulated insulin secretion triggered?
Glucose metabolism raises ATP/ADP, closes KATP channels, depolarizes the beta cell and opens calcium channels, triggering granule fusion.
What are the two phases of insulin secretion?
The first phase is rapid release of primed granules; the second phase is sustained release requiring granule mobilization and priming.
Which cell lines are used to study insulin secretion?
Human beta cell lines such as 1.1B4 and 1.1E7 are used because they retain glucose responsiveness.
Can CRISPR be used to study insulin secretion genes?
Yes, CRISPR knockout, knock-in and overexpression in beta cell lines allow causal testing of candidate regulators.
What diseases are linked to defects in insulin secretion?
Type 2 diabetes, monogenic diabetes and congenital hyperinsulinism are linked to defects in this pathway.
How does the nervous system affect insulin secretion?
Sympathetic innervation can desensitize alpha-adrenergic inhibition of insulin secretion, modulating the secretory set point.
What methods measure insulin secretion?
ELISA, perifusion, live-cell imaging, patch-clamp and calcium imaging are commonly used.
How can I find positive regulators of insulin secretion?
CRISPR library screening combined with secretion assays can identify genes that enhance glucose-stimulated insulin release.
Conclusion
GO:0035774 provides a precise framework for studying how cells amplify insulin release in response to glucose. Its molecular basis involves glucose sensing, granule trafficking, SNARE-mediated fusion and calcium signaling, with modulation by neural inputs. Understanding this process is essential for diabetes research and for developing therapies that restore beta cell function. CRISPR-based models and functional assays are powerful tools to dissect the underlying genes and mechanisms.
References
- 1. Wang Z et al.. 2009. Mechanisms of biphasic insulin-granule exocytosis - roles of the cytoskeleton, small GTPases and SNARE proteins.. J Cell Sci 122(Pt 7):893-903 PMID: 19295123
- 2. McCluskey JT et al.. 2011. Development and functional characterization of insulin-releasing human pancreatic beta cell lines produced by electrofusion.. J Biol Chem 286(25):21982-92 PMID: 21515691
- 3. Grodsky GM et al.. 1997. Chronic sympathetic innervation of islets in transgenic mice results in differential desensitization of alpha-adrenergic inhibition of insulin secretion.. Adv Exp Med Biol 426:129-38 PMID: 9544265
